Chiasma Inc (CHMA) Sinks on FDA Speculation

Speculation is swirling that the Food and Drug Administration (FDA) will reject Chiasma Inc's (NASDAQ:CHMA) acromegaly treatment

by Karee Venema

Published on Apr 14, 2016 at 2:58 PM

It's a pretty mild day for the broader stock market, but biotech stock Chiasma Inc (NASDAQ:CHMA) is seeing some action. Specifically, the stock has plunged 13.8% to $9.40 -- after earlier being off by more than 17% -- on speculation the Food and Drug Administration (FDA) is preparing to reject Chiasma's oral treatment for acromegaly, a rare disease affecting the pituitary gland.

However, this negative price action is nothing new for Wall Street freshman CHMA, which is down 69% from its mid-August all-time high of $30.52. What's more, the stock's recent rally attempt was quickly halted by its 80-day moving average. CHMA has only closed north of this trendline twice since it was formed in mid-November.

Daily chart of CHMA

Short sellers, meanwhile, have been bracing for more downside. Short interest jumped 8.3% in the last two reporting periods, and now accounts for a lofty 12.5% of CHMA's available float. It would take almost a week to cover these shorted shares, at the stock's average daily pace of trading.

Analysts, however, have a taken a glass-half-full approach to CHMA. In fact, all four analysts covering the shares maintain a "strong buy" rating on the equity. Should Chiasma Inc (NASDAQ:CHMA) continue to struggle both on and off the charts, a round of downgrades could create more headwinds for the shares.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical  levels, and top economic stories straight to your inbox.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.
3M Ramps Up Face Mask Production on White House Order, Stock Slips
President Trump said he would invoked the Defense Production Act against 3M in a tweet late on Thursday
Apple Keeps U.S. Stores Closed Until Early May
AAPL puts have risen in popularity
Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.